首页 > 最新文献

Journal of Surgical Oncology最新文献

英文 中文
Correction to “Clinical Characteristics and Genomic Profile of Malignant Proliferating Trichilemmal Tumor: A Systematic Review of the Literature” 修正“恶性增生性毛管肿瘤的临床特征和基因组图谱:文献系统综述”。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-12 DOI: 10.1002/jso.70184

Hanson, N., Farmer, W., Andres, M., Franko, J. and Le, V. (2025), Clinical Characteristics and Genomic Profile of Malignant Proliferating Trichilemmal Tumor: A Systematic Review of the Literature. Journal of Surgical Oncology, 131: 1074-1080. https://doi.org/10.1002/jso.27925

In Figure 1, the Prisma Flow Diagram, there was an error in the tabulated numbers. The final number of review articles was 29, but the number of removed articles stated 165. This was an error in calculation, and it was actually 163 from the original 192 to get 29.

The corrected figure is shown below.

We apologize for this error.

Hanson, N., Farmer, W., Andres, M., Franko, J.和Le, V.(2025),恶性增殖性毛管肿瘤的临床特征和基因组谱:文献的系统回顾。中华外科杂志,31:1074-1080。https://doi.org/10.1002/jso.27925In图1,Prisma流程图,在表格数字中有一个错误。最终的评论文章数为29篇,但被删除的文章数为165篇。这是一个计算错误,实际上是163从原来的192变成了29。更正后的数字如下所示。我们为这个错误道歉。
{"title":"Correction to “Clinical Characteristics and Genomic Profile of Malignant Proliferating Trichilemmal Tumor: A Systematic Review of the Literature”","authors":"","doi":"10.1002/jso.70184","DOIUrl":"10.1002/jso.70184","url":null,"abstract":"<p>Hanson, N., Farmer, W., Andres, M., Franko, J. and Le, V. (2025), Clinical Characteristics and Genomic Profile of Malignant Proliferating Trichilemmal Tumor: A Systematic Review of the Literature. Journal of Surgical Oncology, 131: 1074-1080. https://doi.org/10.1002/jso.27925</p><p>In Figure 1, the Prisma Flow Diagram, there was an error in the tabulated numbers. The final number of review articles was 29, but the number of removed articles stated 165. This was an error in calculation, and it was actually 163 from the original 192 to get 29.</p><p>The corrected figure is shown below.</p><p>We apologize for this error.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"133 2","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiomics in Pancreatic Neuroendocrine Tumors (PNETs): Current Evidence, Reproducibility Gaps, and Research Directions 胰腺神经内分泌肿瘤(PNETs)的放射组学:目前的证据、可重复性差距和研究方向。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-12 DOI: 10.1002/jso.70177
Abdallah Attia, Sydney Wellens, Kristen Limbach

Radiomics is a growing field for diagnosis, prognostication, and therapeutic decision-making in numerous solid tumors. Despite current promising findings in pancreatic neuroendocrine tumors (PNETs), significant limitations persist, including small cohorts, heterogeneous imaging protocols, and lack of external validation. This review elucidates the radiomics workflow, critically synthesizes the current evidence specifically surrounding the use of radiomics in PNETs, explicitly identifies methodological and reproducibility gaps, and outlines pragmatic research directions to bridge current drawbacks.

放射组学在许多实体肿瘤的诊断、预后和治疗决策方面是一个不断发展的领域。尽管目前在胰腺神经内分泌肿瘤(PNETs)中有很好的发现,但仍然存在显着的局限性,包括小队列,异质成像方案和缺乏外部验证。这篇综述阐述了放射组学的工作流程,批判性地综合了目前关于放射组学在PNETs中使用的证据,明确地确定了方法学和可重复性的差距,并概述了实用的研究方向,以弥补目前的不足。
{"title":"Radiomics in Pancreatic Neuroendocrine Tumors (PNETs): Current Evidence, Reproducibility Gaps, and Research Directions","authors":"Abdallah Attia,&nbsp;Sydney Wellens,&nbsp;Kristen Limbach","doi":"10.1002/jso.70177","DOIUrl":"10.1002/jso.70177","url":null,"abstract":"<div>\u0000 \u0000 <p>Radiomics is a growing field for diagnosis, prognostication, and therapeutic decision-making in numerous solid tumors. Despite current promising findings in pancreatic neuroendocrine tumors (PNETs), significant limitations persist, including small cohorts, heterogeneous imaging protocols, and lack of external validation. This review elucidates the radiomics workflow, critically synthesizes the current evidence specifically surrounding the use of radiomics in PNETs, explicitly identifies methodological and reproducibility gaps, and outlines pragmatic research directions to bridge current drawbacks.</p></div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"133 2","pages":"161-169"},"PeriodicalIF":1.9,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “Circulating Levels of Galectin-9 Are a Potential Biomarker of Survival in Advanced Non-Small-Cell Lung Cancer” 更正“循环半乳糖凝集素-9水平是晚期非小细胞肺癌患者生存的潜在生物标志物”。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-12 DOI: 10.1002/jso.70188

Filho GVdM, Costa GJ, Martins MR, Torres LC. Circulating levels of galectin-9 are a potential biomarker of survival in advanced non-small-cell lung cancer. J Surg Oncol. 2024; 130: 913-918. https://doi.org/10.1002/jso.27758.

In paragraph 2.1 of the Methods section, add a third paragraph to the text “The criteria for exclusion were pregnant or lactating patients, patients with psychiatric disorders, patients with a clinical history of HIV I/II or HTLV I/II infection, patients with a clinical history of autoimmune or infectious diseases, patients with a previous diagnosis and treatment for another type of malignant tumor and patients who had undergone prior chemotherapy, immunotherapy, or radiotherapy.

In paragraph 2.3 of the Methods section, remove the incorrect paragraph “A Kaplan–Meier curve with log-rank test was performed for survival time between sGal-9 ≤ 1,694 and > 1,694 groups and smoking status (smokers vs non-smokers)” and replace it with the text “The median survival time was calculated using a specific Gal9 cutoff value. The median survival using the Gal9 cutoff less than or equal to 1694 pg/mL was 15.9 months and undefined for the above cutoff point 1694 pg/mL.”

We apologize for these errors.

Filho GVdM, Costa GJ, Martins MR, Torres LC。半乳糖凝集素-9的循环水平是晚期非小细胞肺癌患者生存的潜在生物标志物。中华外科杂志;2024;130: 913 - 918。https://doi.org/10.1002/jso.27758.In方法部分第2.1段,在文本中增加第三段“排除标准为孕妇或哺乳期患者、精神疾病患者、有HIV I/II或HTLV I/II感染临床病史的患者、有自身免疫性疾病或感染性疾病临床病史的患者、以前诊断和治疗过其他类型恶性肿瘤的患者以及之前接受过化疗的患者。免疫疗法,或放疗。在方法部分第2.3段中,删除不正确的段落“使用Kaplan-Meier曲线对sGal-9≤1694和>; 1694组之间的生存时间和吸烟状态(吸烟者与非吸烟者)进行log-rank检验”,并将其替换为“使用特定的Gal9截止值计算中位生存时间”。使用小于或等于1694 pg/mL的Gal9截断点的中位生存期为15.9个月,对于上述截断点1694 pg/mL未定义。”我们为这些错误道歉。
{"title":"Correction to “Circulating Levels of Galectin-9 Are a Potential Biomarker of Survival in Advanced Non-Small-Cell Lung Cancer”","authors":"","doi":"10.1002/jso.70188","DOIUrl":"10.1002/jso.70188","url":null,"abstract":"<p>Filho GVdM, Costa GJ, Martins MR, Torres LC. Circulating levels of galectin-9 are a potential biomarker of survival in advanced non-small-cell lung cancer. <i>J Surg Oncol</i>. 2024; 130: 913-918. https://doi.org/10.1002/jso.27758.</p><p>In paragraph 2.1 of the Methods section, add a third paragraph to the text “The criteria for exclusion were pregnant or lactating patients, patients with psychiatric disorders, patients with a clinical history of HIV I/II or HTLV I/II infection, patients with a clinical history of autoimmune or infectious diseases, patients with a previous diagnosis and treatment for another type of malignant tumor and patients who had undergone prior chemotherapy, immunotherapy, or radiotherapy.</p><p>In paragraph 2.3 of the Methods section, remove the incorrect paragraph “A Kaplan–Meier curve with log-rank test was performed for survival time between sGal-9 ≤ 1,694 and &gt; 1,694 groups and smoking status (smokers vs non-smokers)” and replace it with the text “The median survival time was calculated using a specific Gal9 cutoff value. The median survival using the Gal9 cutoff less than or equal to 1694 pg/mL was 15.9 months and undefined for the above cutoff point 1694 pg/mL.”</p><p>We apologize for these errors.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"133 2","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Prognostic Utility of Circulating Tumor DNA Methylation Analysis in Stage IV Colorectal Cancer". 修正“循环肿瘤DNA甲基化分析在IV期结直肠癌中的预后效用”。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-11 DOI: 10.1002/jso.70186
{"title":"Correction to \"Prognostic Utility of Circulating Tumor DNA Methylation Analysis in Stage IV Colorectal Cancer\".","authors":"","doi":"10.1002/jso.70186","DOIUrl":"https://doi.org/10.1002/jso.70186","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulin-Dependence and Survival in Pancreatic Neuroendocrine Tumors: Results From the US-NTSG Group 胰腺神经内分泌肿瘤的胰岛素依赖和生存:来自US-NTSG组的结果。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-11 DOI: 10.1002/jso.70174
Muhammad Bilal Mirza, Jordan J. Baechle, Paula Marincola Smith, Danish Ali, Mary Dillhoff, George Poultsides, Flavio G. Rocha, Clifford S. Cho, Emily R. Winslow, Ryan C. Fields, Shishir K. Maithel, Kamran Idrees

Introduction

PNETs are rare pancreatic malignancies originating from islet cells and exhibit a strong co-occurrence with Diabetes Mellitus (DM), associated with worse survival outcomes. However, studies have yet to delineate the impact of insulin dependent (IDDM) and non-insulin dependent (NIDDM) on poor oncological outcomes.

Methods

Utilizing the U.S. Neuroendocrine Tumor Study Group database (1999-2016), we performed a retrospective cohort study of adult patients who underwent primary surgical resection of PNETs. Patients were categorized based on preoperative diagnosis into non-DM, NIDDM, and IDDM cohorts. We used the Kaplan-Meier method and log-rank test to study cancer-specific survival (CSS). Cox proportional Hazards models were used to assess the impact of IDDM on CSS.

Results

Of the 1122 patients included in the analysis, 870 (77%) were non-DM, 168 (15%) were NIDDM, and 84 (8%) were IDDM. The groups were similar in tumor stage and grade. However, they differed in sex, BMI, age, ASA class, tumor location, preoperative HbA1c, and serum glucose (p-value < 0.05). Patients with IDDM had significantly decreased 5-year CSS compared to patients without IDDM (CSS: IDDM 85%, NIDDM 94%, non-DM 93%, NIDDM + non-DM 93%; p < 0.01). On multivariate analysis, IDDM was independently associated with worse CSS (HR 2.27, 95% Confidence Interval 1.15−4.45, p = 0.02).

Conclusion

Insulin dependence is associated with worse cancer-specific survival in PNET patients following surgical resection compared to PNET patients with NIDDM or without DM.

PNETs是一种罕见的胰腺恶性肿瘤,起源于胰岛细胞,并与糖尿病(DM)共同发生,与较差的生存结果相关。然而,研究尚未描述胰岛素依赖型(IDDM)和非胰岛素依赖型(NIDDM)对不良肿瘤预后的影响。方法:利用美国神经内分泌肿瘤研究小组数据库(1999-2016),我们对接受原发性PNETs手术切除的成年患者进行了回顾性队列研究。根据术前诊断将患者分为非糖尿病组、非糖尿病组和非糖尿病组。我们采用Kaplan-Meier法和log-rank检验来研究癌症特异性生存(CSS)。采用Cox比例风险模型评估IDDM对CSS的影响。结果:纳入分析的1122例患者中,870例(77%)为非糖尿病,168例(15%)为NIDDM, 84例(8%)为IDDM。两组肿瘤分期、分级相似。然而,他们在性别、BMI、年龄、ASA类别、肿瘤位置、术前HbA1c和血清葡萄糖方面存在差异(p值)。结论:与合并NIDDM或无DM的PNET患者相比,手术切除后PNET患者的胰岛素依赖与更差的癌症特异性生存相关。
{"title":"Insulin-Dependence and Survival in Pancreatic Neuroendocrine Tumors: Results From the US-NTSG Group","authors":"Muhammad Bilal Mirza,&nbsp;Jordan J. Baechle,&nbsp;Paula Marincola Smith,&nbsp;Danish Ali,&nbsp;Mary Dillhoff,&nbsp;George Poultsides,&nbsp;Flavio G. Rocha,&nbsp;Clifford S. Cho,&nbsp;Emily R. Winslow,&nbsp;Ryan C. Fields,&nbsp;Shishir K. Maithel,&nbsp;Kamran Idrees","doi":"10.1002/jso.70174","DOIUrl":"10.1002/jso.70174","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>PNETs are rare pancreatic malignancies originating from islet cells and exhibit a strong co-occurrence with Diabetes Mellitus (DM), associated with worse survival outcomes. However, studies have yet to delineate the impact of insulin dependent (IDDM) and non-insulin dependent (NIDDM) on poor oncological outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Utilizing the U.S. Neuroendocrine Tumor Study Group database (1999-2016), we performed a retrospective cohort study of adult patients who underwent primary surgical resection of PNETs. Patients were categorized based on preoperative diagnosis into non-DM, NIDDM, and IDDM cohorts. We used the Kaplan-Meier method and log-rank test to study cancer-specific survival (CSS). Cox proportional Hazards models were used to assess the impact of IDDM on CSS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1122 patients included in the analysis, 870 (77%) were non-DM, 168 (15%) were NIDDM, and 84 (8%) were IDDM. The groups were similar in tumor stage and grade. However, they differed in sex, BMI, age, ASA class, tumor location, preoperative HbA1c, and serum glucose (<i>p</i>-value &lt; 0.05). Patients with IDDM had significantly decreased 5-year CSS compared to patients without IDDM (CSS: IDDM 85%, NIDDM 94%, non-DM 93%, NIDDM + non-DM 93%; <i>p</i> &lt; 0.01). On multivariate analysis, IDDM was independently associated with worse CSS (HR 2.27, 95% Confidence Interval 1.15−4.45, <i>p</i> = 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Insulin dependence is associated with worse cancer-specific survival in PNET patients following surgical resection compared to PNET patients with NIDDM or without DM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"133 2","pages":"153-160"},"PeriodicalIF":1.9,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12863235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Chemotherapy Switch for Non-Response or Progression on Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma". 修正“胰腺腺癌新辅助化疗无反应或进展的化疗切换”。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-11 DOI: 10.1002/jso.70187
{"title":"Correction to \"Chemotherapy Switch for Non-Response or Progression on Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma\".","authors":"","doi":"10.1002/jso.70187","DOIUrl":"https://doi.org/10.1002/jso.70187","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis. 四肢软组织肉瘤血管重建:一项系统综述和单组荟萃分析。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1002/jso.70194
Lucas Monteiro Delgado, Bernardo Fontel Pompeu, Vinícius Dos Santos Macedo, Gabriel Henrique Acedo Martins, Eric Pasqualotto, Matheus Reginato Araujo, Julia Hoici Brunini, Victor Andrade Nunes, Cláudia Theis, Samuel Aguiar Junior

Introduction: The management of extremity soft tissue sarcomas (STS) involving major vessels presents unique challenges, historically leading to amputation. Advances in vascular reconstruction have enabled limb-sparing surgery (LSS), but outcomes and perioperative risks remain uncertain. This systematic review and meta-analysis aimed to evaluate oncologic results following LSS with vascular reconstruction in extremity STS.

Methods: A systematic review and single-arm meta-analysis were performed according to PRISMA guidelines, with registration in PROSPERO. PubMed, Embase, and Cochrane Library were searched from inception to June 2025 for studies reporting outcomes in patients with extremity STS undergoing LSS with vascular reconstruction. Pooled analyses estimated limb salvage, survival, and complication rates using random-effects models.

Results: Thirty-one studies comprising 520 patients were included. Approximately 58% were male, with a mean age ranging from 29.3 to 59 years. The most common tumor localizations were the thigh (59.5%), inguinal region (15.9%), and popliteal fossa (8.6%). Liposarcoma (24.0%), synovial sarcoma (19.6%), and osteosarcoma (14.8%) were the most frequent histological subtypes. The pooled limb salvage rate was 89% (95% CI, 86%-92%), while amputation occurred in 10% (95% CI, 8%-14%). One- and 5-year overall survival rates were 89% and 62%, respectively, with disease-free survival rates of 74% and 55%. Major complications included graft thrombosis (19%), wound complications (29%), and wound infection (22%).

Conclusions: Limb-sparing surgery with vascular reconstruction is effective for extremity STS involving major vessels, enabling high limb salvage and favorable long-term survival without compromising oncologic outcomes. However, substantial perioperative morbidity persists, underscoring the need for multidisciplinary care, careful patient selection, and prospective studies to refine indications and enhance quality of life.

简介:四肢软组织肉瘤(STS)涉及主要血管的管理提出了独特的挑战,历史上导致截肢。血管重建的进步使保肢手术(LSS)成为可能,但结果和围手术期风险仍然不确定。本系统综述和荟萃分析旨在评估肢体STS患者LSS合并血管重建后的肿瘤学结果。方法:根据PRISMA指南进行系统评价和单臂荟萃分析,并在PROSPERO注册。PubMed、Embase和Cochrane图书馆检索了从成立到2025年6月报道肢体STS患者行LSS合并血管重建结果的研究。采用随机效应模型进行汇总分析,估计残肢保留、生存率和并发症发生率。结果:纳入了31项研究,包括520例患者。约58%为男性,平均年龄在29.3岁至59岁之间。最常见的肿瘤定位是大腿(59.5%)、腹股沟区(15.9%)和腘窝(8.6%)。脂肪肉瘤(24.0%)、滑膜肉瘤(19.6%)和骨肉瘤(14.8%)是最常见的组织学亚型。合并肢体保留率为89% (95% CI, 86%-92%),而截肢发生率为10% (95% CI, 8%-14%)。1年和5年总生存率分别为89%和62%,无病生存率为74%和55%。主要并发症包括移植物血栓形成(19%)、伤口并发症(29%)和伤口感染(22%)。结论:保留肢体的血管重建手术对涉及大血管的肢体STS是有效的,可以在不影响肿瘤预后的情况下实现高肢体保留和良好的长期生存。然而,大量围手术期发病率持续存在,强调需要多学科护理,仔细选择患者,并进行前瞻性研究以改善适应症和提高生活质量。
{"title":"Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis.","authors":"Lucas Monteiro Delgado, Bernardo Fontel Pompeu, Vinícius Dos Santos Macedo, Gabriel Henrique Acedo Martins, Eric Pasqualotto, Matheus Reginato Araujo, Julia Hoici Brunini, Victor Andrade Nunes, Cláudia Theis, Samuel Aguiar Junior","doi":"10.1002/jso.70194","DOIUrl":"https://doi.org/10.1002/jso.70194","url":null,"abstract":"<p><strong>Introduction: </strong>The management of extremity soft tissue sarcomas (STS) involving major vessels presents unique challenges, historically leading to amputation. Advances in vascular reconstruction have enabled limb-sparing surgery (LSS), but outcomes and perioperative risks remain uncertain. This systematic review and meta-analysis aimed to evaluate oncologic results following LSS with vascular reconstruction in extremity STS.</p><p><strong>Methods: </strong>A systematic review and single-arm meta-analysis were performed according to PRISMA guidelines, with registration in PROSPERO. PubMed, Embase, and Cochrane Library were searched from inception to June 2025 for studies reporting outcomes in patients with extremity STS undergoing LSS with vascular reconstruction. Pooled analyses estimated limb salvage, survival, and complication rates using random-effects models.</p><p><strong>Results: </strong>Thirty-one studies comprising 520 patients were included. Approximately 58% were male, with a mean age ranging from 29.3 to 59 years. The most common tumor localizations were the thigh (59.5%), inguinal region (15.9%), and popliteal fossa (8.6%). Liposarcoma (24.0%), synovial sarcoma (19.6%), and osteosarcoma (14.8%) were the most frequent histological subtypes. The pooled limb salvage rate was 89% (95% CI, 86%-92%), while amputation occurred in 10% (95% CI, 8%-14%). One- and 5-year overall survival rates were 89% and 62%, respectively, with disease-free survival rates of 74% and 55%. Major complications included graft thrombosis (19%), wound complications (29%), and wound infection (22%).</p><p><strong>Conclusions: </strong>Limb-sparing surgery with vascular reconstruction is effective for extremity STS involving major vessels, enabling high limb salvage and favorable long-term survival without compromising oncologic outcomes. However, substantial perioperative morbidity persists, underscoring the need for multidisciplinary care, careful patient selection, and prospective studies to refine indications and enhance quality of life.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Term Metabolic Outcomes Following Pancreatectomy and Autologous Islet Transplantation: Systematic Review and Meta-Analysis. 胰腺切除术和自体胰岛移植后的长期代谢结果:系统回顾和荟萃分析。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1002/jso.70193
Daniel L Hughes, Caterina Di Bella, Benedetta Quaratino, Pietro Rigo, Giulia Cirillo, Gioia Sgrinzato, Umberto Cillo, Lucrezia Furian, Giovanni Marchegiani

This systematic review and meta-analysis assessed long-term outcomes following total pancreatectomy with islet autotransplantation (TPIAT). Seventeen studies including 1332 patients were analyzed. The pooled insulin independence rate was 34%, with higher rates for non-chronic pancreatitis indications (68%) versus chronic pancreatitis (33%). TPIAT is effective in preserving endocrine function. Further studies are needed to validate outcomes across extended indications and to standardize reporting, incorporating metabolic markers and patient-reported quality-of-life endpoints over long-term follow-up.

本系统综述和荟萃分析评估了全胰腺切除术合并胰岛自体移植(TPIAT)后的长期结果。17项研究包括1332例患者进行了分析。合并胰岛素独立率为34%,非慢性胰腺炎适应症(68%)高于慢性胰腺炎适应症(33%)。TPIAT对维持内分泌功能有效。需要进一步的研究来验证扩展适应症的结果,并标准化报告,在长期随访中纳入代谢标志物和患者报告的生活质量终点。
{"title":"Long Term Metabolic Outcomes Following Pancreatectomy and Autologous Islet Transplantation: Systematic Review and Meta-Analysis.","authors":"Daniel L Hughes, Caterina Di Bella, Benedetta Quaratino, Pietro Rigo, Giulia Cirillo, Gioia Sgrinzato, Umberto Cillo, Lucrezia Furian, Giovanni Marchegiani","doi":"10.1002/jso.70193","DOIUrl":"https://doi.org/10.1002/jso.70193","url":null,"abstract":"<p><p>This systematic review and meta-analysis assessed long-term outcomes following total pancreatectomy with islet autotransplantation (TPIAT). Seventeen studies including 1332 patients were analyzed. The pooled insulin independence rate was 34%, with higher rates for non-chronic pancreatitis indications (68%) versus chronic pancreatitis (33%). TPIAT is effective in preserving endocrine function. Further studies are needed to validate outcomes across extended indications and to standardize reporting, incorporating metabolic markers and patient-reported quality-of-life endpoints over long-term follow-up.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Mapping Review of Core Outcome Reporting in Surgical Research for Oesophageal Cancer. 食管癌外科研究核心结果报告的系统制图综述。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-07 DOI: 10.1002/jso.70173
Nadia Matias, Anie Naqvi, Jack Thomson, Roukia Techache, Kerry Avery, Natalie Blencowe, Rhiannon Macefield, Bilal Alkhaffaf

Oesophageal carcinoma is a rising global health burden, with surgical resection and perioperative chemotherapy forming the cornerstone of curative treatment. However, uncertainty persists regarding the optimal surgical approach, partly due to heterogeneity in outcome reporting, which hinders data synthesis and evidence-based decision-making. To address this, a core outcome set (COS) for oesophageal cancer surgery was developed through international consensus among clinicians and patients. This study systematically evaluates the uptake of these core outcomes in contemporary surgical research. A systematic review was conducted of randomised controlled trials and prospective cohort studies investigating oesophagectomy for oesophageal cancer, published between 2010 and 2024. The reporting of ten COS-recommended outcomes was assessed across eligible studies. Fifty-eight studies involving 22 260 patients were included (39 cohort studies; 19 RCTs). No study reported all 10 core outcomes. The median number of core outcomes reported was 4 (interquartile range 3-5). The frequency of individual core outcome reporting was as follows: in-hospital mortality (86%), conduit necrosis/leak (81%), respiratory complications (79%), overall survival (30%), ability to eat and drink (44%), quality of life (26%), inoperability (23%), reflux symptoms (21%), severe nutritional effects (19%), and need for reintervention (16%). No improvement in core outcome reporting was observed over the study period. Promoting COS implementation and improving methodological rigour is essential to ensure that future research reflects the priorities of both clinicians and patients, and facilitates meaningful evidence synthesis.

食管癌是一个日益严重的全球健康负担,手术切除和围手术期化疗是根治性治疗的基石。然而,关于最佳手术方法的不确定性仍然存在,部分原因是结果报告的异质性,这阻碍了数据合成和循证决策。为了解决这个问题,通过临床医生和患者之间的国际共识,制定了食管癌手术的核心结局集(COS)。本研究系统地评估了这些核心结果在当代外科研究中的应用。对2010年至2024年间发表的调查食管癌食管癌切除术的随机对照试验和前瞻性队列研究进行了系统回顾。在符合条件的研究中评估了cos推荐的十个结果的报告。纳入58项研究,涉及22260例患者(39项队列研究;19项随机对照试验)。没有研究报告了全部10项核心结果。报告的核心结果中位数为4个(四分位数范围为3-5)。个别核心结局报告的频率如下:住院死亡率(86%),导管坏死/渗漏(81%),呼吸系统并发症(79%),总生存率(30%),饮食能力(44%),生活质量(26%),不可操作性(23%),反流症状(21%),严重营养不良(19%),需要再干预(16%)。在研究期间,没有观察到核心结果报告的改善。促进COS的实施和提高方法的严谨性对于确保未来的研究反映临床医生和患者的优先事项并促进有意义的证据合成至关重要。
{"title":"A Systematic Mapping Review of Core Outcome Reporting in Surgical Research for Oesophageal Cancer.","authors":"Nadia Matias, Anie Naqvi, Jack Thomson, Roukia Techache, Kerry Avery, Natalie Blencowe, Rhiannon Macefield, Bilal Alkhaffaf","doi":"10.1002/jso.70173","DOIUrl":"https://doi.org/10.1002/jso.70173","url":null,"abstract":"<p><p>Oesophageal carcinoma is a rising global health burden, with surgical resection and perioperative chemotherapy forming the cornerstone of curative treatment. However, uncertainty persists regarding the optimal surgical approach, partly due to heterogeneity in outcome reporting, which hinders data synthesis and evidence-based decision-making. To address this, a core outcome set (COS) for oesophageal cancer surgery was developed through international consensus among clinicians and patients. This study systematically evaluates the uptake of these core outcomes in contemporary surgical research. A systematic review was conducted of randomised controlled trials and prospective cohort studies investigating oesophagectomy for oesophageal cancer, published between 2010 and 2024. The reporting of ten COS-recommended outcomes was assessed across eligible studies. Fifty-eight studies involving 22 260 patients were included (39 cohort studies; 19 RCTs). No study reported all 10 core outcomes. The median number of core outcomes reported was 4 (interquartile range 3-5). The frequency of individual core outcome reporting was as follows: in-hospital mortality (86%), conduit necrosis/leak (81%), respiratory complications (79%), overall survival (30%), ability to eat and drink (44%), quality of life (26%), inoperability (23%), reflux symptoms (21%), severe nutritional effects (19%), and need for reintervention (16%). No improvement in core outcome reporting was observed over the study period. Promoting COS implementation and improving methodological rigour is essential to ensure that future research reflects the priorities of both clinicians and patients, and facilitates meaningful evidence synthesis.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brazilian Society of Surgical Oncology: Guidelines and Consensus Statement for Palliative Surgery in Oncology. 巴西肿瘤外科学会:肿瘤姑息性手术指南和共识声明。
IF 1.9 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-07 DOI: 10.1002/jso.70189
Audrey Cabral Ferreira de Oliveira, Jordana Henz Hammes, Isabela Maria Alves de Almeida Oliva, Lara Andrade Mendes Mangieri, Ronald Enrique Delgado Bocanegra, Marcos Gonçalves Adriano Junior, Ana Caroline Fonseca Alves, Eliel Oliveira de Araujo, Jairo Cerqueira de Almeida Teixeira, Patricia Isabel Bahia Mendes Freire, Larissa de Jesus Almeida, Raquel Lacerda Dantas de Farias, Heládio Feitosa E Castro Neto, Alexandre Ferreira Oliveira, Reitan Ribeiro, Rodrigo Nascimento Pinheiro

Background and objective: Palliative surgery in oncology aims to relieve symptoms, improve quality of life, and respect patient autonomy in advanced cancer. This study aimed to develop evidence-based recommendations for safely indicating and performing palliative surgeries in Brazil, considering clinical, ethical, and multidisciplinary aspects.

Methods: A modified Delphi consensus was conducted with nine experts from the Brazilian Society of Surgical Oncology, including surgical and clinical oncologists, palliative care specialists, and a psychologist. Sixteen key recommendations were formulated based on literature review and a national survey identifying gaps in training, communication, and technical safety. Consensus was defined as ≥ 80% agreement, achieved in a single round.

Results: Recommendations emphasize individualized patient selection based on functional status, frailty, prognosis, and symptom severity. Multidisciplinary evaluation, shared decision-making, clear communication, and consideration of minimally invasive techniques were prioritized. Palliative procedures focus on symptom control rather than survival extension, with evidence supporting improved quality of life, reduced hospital admissions, and enhanced oral intake.

Conclusions: Palliative surgery should be guided by strict clinical criteria, multidisciplinary planning, and patient-centered communication. Active patient participation, ethical deliberation, and evidence-based practices ensure safe, effective, and humanized care, avoiding futile or disproportionate interventions.

背景与目的:肿瘤姑息性手术旨在缓解晚期肿瘤患者的症状,提高生活质量,并尊重患者的自主权。本研究旨在考虑临床、伦理和多学科方面,为巴西安全指示和实施姑息性手术制定循证建议。方法:与来自巴西外科肿瘤学会的9位专家进行了修改的德尔菲共识,包括外科和临床肿瘤学家、姑息治疗专家和一位心理学家。根据文献综述和一项确定培训、沟通和技术安全方面差距的全国调查,制定了16项关键建议。共识被定义为≥80%的共识,在单轮中达成。结果:建议强调基于功能状态、虚弱、预后和症状严重程度的个体化患者选择。多学科评估、共同决策、明确沟通和考虑微创技术是优先考虑的。姑息治疗程序侧重于症状控制,而不是延长生存期,有证据支持改善生活质量、减少住院次数和增加口服摄入量。结论:姑息性手术应以严格的临床标准、多学科规划和以患者为中心的沟通为指导。积极的患者参与、伦理审议和循证实践确保了安全、有效和人性化的护理,避免了无效或不成比例的干预。
{"title":"Brazilian Society of Surgical Oncology: Guidelines and Consensus Statement for Palliative Surgery in Oncology.","authors":"Audrey Cabral Ferreira de Oliveira, Jordana Henz Hammes, Isabela Maria Alves de Almeida Oliva, Lara Andrade Mendes Mangieri, Ronald Enrique Delgado Bocanegra, Marcos Gonçalves Adriano Junior, Ana Caroline Fonseca Alves, Eliel Oliveira de Araujo, Jairo Cerqueira de Almeida Teixeira, Patricia Isabel Bahia Mendes Freire, Larissa de Jesus Almeida, Raquel Lacerda Dantas de Farias, Heládio Feitosa E Castro Neto, Alexandre Ferreira Oliveira, Reitan Ribeiro, Rodrigo Nascimento Pinheiro","doi":"10.1002/jso.70189","DOIUrl":"10.1002/jso.70189","url":null,"abstract":"<p><strong>Background and objective: </strong>Palliative surgery in oncology aims to relieve symptoms, improve quality of life, and respect patient autonomy in advanced cancer. This study aimed to develop evidence-based recommendations for safely indicating and performing palliative surgeries in Brazil, considering clinical, ethical, and multidisciplinary aspects.</p><p><strong>Methods: </strong>A modified Delphi consensus was conducted with nine experts from the Brazilian Society of Surgical Oncology, including surgical and clinical oncologists, palliative care specialists, and a psychologist. Sixteen key recommendations were formulated based on literature review and a national survey identifying gaps in training, communication, and technical safety. Consensus was defined as ≥ 80% agreement, achieved in a single round.</p><p><strong>Results: </strong>Recommendations emphasize individualized patient selection based on functional status, frailty, prognosis, and symptom severity. Multidisciplinary evaluation, shared decision-making, clear communication, and consideration of minimally invasive techniques were prioritized. Palliative procedures focus on symptom control rather than survival extension, with evidence supporting improved quality of life, reduced hospital admissions, and enhanced oral intake.</p><p><strong>Conclusions: </strong>Palliative surgery should be guided by strict clinical criteria, multidisciplinary planning, and patient-centered communication. Active patient participation, ethical deliberation, and evidence-based practices ensure safe, effective, and humanized care, avoiding futile or disproportionate interventions.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1